Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 11,177 matching trials from the live ClinicalTrials.gov search.
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Atezolizumab, Enfortumab Vedotin, Niraparib, Magrolimab (Hu5F9-G4), Tiragolumab, Sacituzumab Govitecan, Tocilizumab, Cisplatin, Gemcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 6 more
Conditions
Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma
Interventions
Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2, retifanlimab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
20
States / cities
Scottsdale, Arizona • Newark, Delaware • Jacksonville, Florida + 17 more
Conditions
Ovarian Cancer, Solid Tumor
Interventions
CUSP06
Drug
Lead sponsor
OnCusp Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Denver, Colorado • New Haven, Connecticut • Miami Beach, Florida + 9 more
Completed Phase 1Phase 2 Interventional Results available

FX-322 in Sensorineural Hearing Loss

NCT03616223
Conditions
Sensorineural Hearing Loss
Interventions
FX-322, Placebo
Drug
Lead sponsor
Frequency Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Exploring, Predicting, and Intervening on Long-term Viral Suppression Electronically

NCT06370780
Conditions
HIV Infections
Interventions
EPI LOVE
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Active, not recruiting No phase listed Observational

An Ophthalmic Safety Study in Patients With Breast Cancer

NCT06767462
Conditions
Ophthalmic Safety in Patients With Breast Cancer
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
La Jolla, California • Palo Alto, California • Iowa City, Iowa + 6 more
Conditions
Preeclampsia
Interventions
Pravastatin, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
3
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania • Galveston, Texas
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma
Interventions
FT-1101, Azacitidine
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Los Angeles, California • Sarasota, Florida • Tampa, Florida + 5 more
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study of Etravirine and GSK1265744

NCT00920296
Conditions
Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions
GSK1265744
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
COVID-19
Interventions
hAd5-S-Fusion+N-ETSD vaccine
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
El Segundo, California • Newport Beach, California
Conditions
Malignant Melanoma
Interventions
MDX-010
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
4
States / cities
Tucson, Arizona • Los Angeles, California • Charlotte, North Carolina + 1 more
Conditions
Malignant Melanoma, Squamous Cell Carcinoma of Skin
Interventions
THOR-707, Cemiplimab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Beverly Hills, California
Conditions
Depression, Anxiety, Addiction, Emotion, Craving, Stress
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Gastroenteritis Norovirus
Interventions
Norovirus GII.4 Challenge Pool CIN-1, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Gastrointestinal Cancer, Ovarian Cancer, Genitourinary Cancer
Interventions
Aldesleukin, Fludarabine, Cyclophosphamide, KRAS TCR-Transduced PBL, GRT-C903/GRT-R904
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Hutrukin to Analyze Safety and PK in Healthy Volunteers

NCT05098080
Conditions
Pharmacokinetics
Interventions
Hutrukin, Placebo
Biological
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Austin, Texas
Conditions
Sexual and Reproductive Health
Interventions
Sexually transmitted infection (STI) testing clinical decision support (CDS) tool
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
13 Years and older
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection

NCT04372017
Conditions
COVID-19, SARS-CoV 2
Interventions
Hydroxychloroquine, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of SPY002-091 in Healthy Volunteers

NCT06672718
Conditions
Healthy
Interventions
SPY002-091, Placebo
Drug · Other
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cypress, California
Conditions
Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Chronic Myelomonocytic Leukemia in Remission, Graft Versus Host Disease, Hodgkin Lymphoma, Minimal Residual Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Severe Aplastic Anemia, Waldenstrom Macroglobulinemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan Hydrochloride, Mycophenolate Mofetil, Sirolimus, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Breast Neoplasms, Obesity
Interventions
Biopsy, Blood draw, Mammogram, MRI
Procedure
Lead sponsor
Tarah J Ballinger, MD
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Carmel, Indiana • Indianapolis, Indiana
Conditions
Non-small-cell Lung Cancer
Interventions
XL647
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
7
States / cities
Port Saint Lucie, Florida • Chicago, Illinois • Urbana, Illinois + 4 more
Conditions
Advanced Solid Tumor
Interventions
ZL-1211
Drug
Lead sponsor
Zai Biopharmaceutical (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Scottsdale, Arizona • Lynwood, California • Indianapolis, Indiana + 7 more
Conditions
Peripheral Artery Disease (PAD)
Interventions
REGN7508, REGN9933, Placebo, Rivaroxaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
30
States / cities
Alexander City, Alabama • Avondale, Arizona • Little Rock, Arkansas + 26 more